LGALS9 and neoplasm: To further address the in vivo role of tumor galectin‐9 in immune modulation, a syngeneic xenograft model was constructed by injecting the mouse lung cancer cell line LLC1 with or without Lgals9 knockdown into C57BL mice and monitoring tumor development as well as intratumoral T‐cell populations.